AQUESTIVE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.28 USD | -2.53% |
|
-16.54% | +62.38% |
| 04-29 | Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children | MT |
| 04-29 | Transcript : Aquestive Therapeutics, Inc. - Special Call |
Chart calendar Aquestive Therapeutics, Inc.
c4bdc024244d301a5d838a38df9b2._OEVDBevgbjpwjOmwrUmJVJ21Iyq_qbM1sfTsxYIi1o.iqonPHTA69Gi91mXkv4XVigAu-vtldT1uYSCwENE5Ti7izh2W8Hn3aWJCw~83b87fbe39acc45b250128699acec3b8
Upcoming events on Aquestive Therapeutics, Inc.
Past events on Aquestive Therapeutics, Inc.
| 29/04/2024 13:00 | Libervant™ FDA Approval Call |
| 17/04/2024 13:00 | American Academy of Neurology Meeting |
| 06/03/2024 13:00 | Q4 2023 Earnings Call |
| 05/03/2024 22:05 | Q4 2023 Earnings Release |
| 23/02/2024 21:15 | American Academy of Allergy, Asthma, and Immunology Meeting - Poster Number: 034 |
| 13/02/2024 20:20 | Oppenheimer Healthcare Life Sciences Conference |
| 10/11/2023 23:45 | American College of Allergy Asthma and Immunology Meeting - Abstract Number - 8053 |
| 10/11/2023 | American College of Allergy Asthma and Immunology Meeting - Abstract Number - 8052 |
| 07/11/2023 13:00 | Q3 2023 Earnings Call |
| 06/11/2023 21:37 | Q3 2023 Earnings Release |
| 13/09/2023 | Lake Street Capital Markets Big7 Conference |
| 11/09/2023 20:30 | H.C. Wainwright Global Investment Conference |
| 08/08/2023 | Wedbush PacGrow Healthcare Conference |
| 08/08/2023 13:00 | Q2 2023 Earnings Call |
| 07/08/2023 21:01 | Q2 2023 Earnings Release |
| 07/07/2023 21:15 | Global Food Allergy Prevention Summit - Poster Number : 11 |
| 07/07/2023 21:15 | Global Food Allergy Prevention Summit - Poster Number : 12 |
| 21/06/2023 14:30 | Annual General Meeting |
| 22/05/2023 | A.G.P Virtual Healthcare Conference |
| 15/05/2023 17:00 | JMP Securities Life Sciences Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 52,6 52,0 1.1% | 45,8 44,9 2.11% | 50,8 49,1 3.52% | 47,7 47,4 0.59% | 50,6 49,0 3.23% | 50,1 |
|
EBITDA Million USD | Released Forecast Spread | -49,8 -47,7 -4.32% | -39,5 -36,8 -7.07% | -31,7 -32,0 0.95% | -35,3 -36,8 3.95% | -11,6 -13,2 12.44% | -22,4 |
|
EBIT Million USD | Released Forecast Spread | -52,7 -50,2 -4.9% | -42,9 -40,4 -6.07% | -34,7 -35,7 2.76% | -42,1 -39,0 -7.82% | -15,1 -15,5 2.45% | -24,1 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -66,2 -65,8 -0.68% | -55,8 -50,4 -10.66% | -70,5 -55,9 -26.08% | -54,4 -55,4 1.82% | -7,63 -4,51 -68.91% | -28,3 |
|
Net income Million USD | Released Forecast Spread | -66,2 -64,4 -2.84% | -55,8 -51,5 -8.26% | -70,5 -57,0 -23.67% | -54,4 -53,2 -2.36% | -7,87 -4,56 -72.66% | -27,7 |
|
EPS USD | Released Forecast Spread | -2,61 -2,51 -4.19% | -1,66 -1,53 -8.21% | -1,85 -1,49 -24.33% | -1,12 -1,08 -3.7% | -0,13 -0,08 -62.5% | -0,36 |
| Announcement Date | 11/03/20 | 09/03/21 | 08/03/22 | 07/03/23 | 05/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 11,1 9,36 18.33% | 12,3 10,1 21.24% | 13,3 10,4 27.74% | 11,5 11,0 3.81% | 10,7 10,4 2.54% | 11,1 9,94 12.04% | 13,2 11,0 20.24% | 13,0 11,5 12.93% | 13,2 11,6 13.54% | 12,3 | 12,6 | 12,6 | 12,6 | 12,8 |
|
EBITDA Million USD | Released Forecast Spread | -10,9 -16,0 31.42% | -9,01 -10,1 10.34% | -9,87 -10,5 5.96% | -7,72 -9,60 19.56% | -9,60 -10,8 11.07% | -3,94 -7,60 48.21% | -3,27 -5,00 34.56% | -1,34 -5,30 74.74% | -2,76 -4,60 40.07% | -4,43 | -5,33 | -5,46 | -7,46 | |
|
EBIT Million USD | Released Forecast Spread | -11,7 -14,6 20.12% | -9,74 -12,7 23.35% | -12,8 -12,4 -2.77% | -8,85 -11,8 24.8% | -10,7 -9,98 -7.36% | -11,1 -7,99 -39.38% | -4,21 -5,63 25.18% | -2,38 -5,05 52.91% | -3,91 -4,82 18.81% | -5,65 | -6,07 | -5,82 | -6,59 | -6,70 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -28,9 -18,8 -53.56% | -13,2 -17,5 24.37% | -16,3 -17,4 6.29% | -12,5 -19,1 34.33% | -12,4 -13,4 7.69% | 8,07 -11,4 170.96% | -5,51 -7,00 21.33% | -2,18 -6,89 68.44% | -8,01 -4,90 -63.33% | -6,29 | -7,11 | -7,03 | -7,95 | |
|
Net income Million USD | Released Forecast Spread | -28,9 -18,8 -53.56% | -13,2 -17,5 24.37% | -16,3 -17,4 6.29% | -12,5 -17,9 29.93% | -12,4 -14,0 11.67% | 8,07 -10,3 178.45% | -5,79 -7,00 17.27% | -2,04 -6,89 70.47% | -8,11 -4,87 -66.52% | -6,24 | -7,06 | -6,98 | -7,90 | |
|
EPS USD | Released Forecast Spread | -0,73 -0,46 -60.09% | -0,32 -0,41 21.57% | -0,36 -0,36 0% | -0,23 -0,31 24.59% | -0,23 -0,23 1.43% | 0,11 -0,19 157.89% | -0,10 -0,11 6.98% | -0,03 -0,12 75% | -0,12 -0,07 -63.64% | -0,08 | -0,09 | -0,09 | -0,10 | -0,07 |
| Announcement Date | 08/03/22 | 04/05/22 | 02/08/22 | 01/11/22 | 07/03/23 | 02/05/23 | 07/08/23 | 06/11/23 | 05/03/24 | - | - | - | - | - |
More events
Past sector events for Aquestive Therapeutics, Inc.
| Today | SCINOPHARM TAIWAN, LTD.: Q1 2024 Earnings Release (Projected) |
| Today | AARTI DRUGS LIMITED: Q4 2024 Earnings Release |
| Today | ALK-ABELLÓ A/S: Q1 2024 Earnings Release |
| Today | DEVA HOLDING: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 12:30 | ORGANON & CO.: Q1 2024 Earnings Release |
| 02/05/2024 06:30 | NOVO NORDISK A/S: Q1 2024 Earnings Release |
| 01/05/2024 | BAUSCH HEALTH COMPANIES INC.: Q1 2024 Earnings Release |
| 01/05/2024 | AMGEN INC.: Q1 2024 Earnings Release |
| 01/05/2024 21:05 | CORCEPT THERAPEUTICS INCORPORATED: Q1 2024 Earnings Release |
| 01/05/2024 21:05 | JAZZ PHARMACEUTICALS PLC: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- AQST Stock
- Calendar Aquestive Therapeutics, Inc.
